Effects of intravenous prostacyclin in variant angina.
Why the study?
Does intravenous prostacyclin reduce ischemic episodes in patients with variant angina?
Population
9 patients with variant angina and 6 normal volunteers (n=15)
Comparison
Intravenous prostacyclin vs Placebo (alternated with PGI2 in one patient)
Design
Case_series
Authors
Discussion
Loading...
Member takes
Implication
Intravenous prostacyclin should not yet change practice in variant angina; leaves open possible response in a minority of patients for prospective study.
Structured PICO
Does intravenous prostacyclin reduce ischemic episodes in patients with variant angina?
P
Population
9 patients with variant angina and 6 normal volunteers (n=15)
I
Intervention
Intravenous prostacyclin (PGI2) (doses of 2.5, 5, 10 and 20 micrograms/kg/min evaluated in normal subjects)
C
Comparator
Placebo (alternated with PGI2 in one patient)
O
Outcome
Number, severity and duration of spontaneous ischemic episodes due to coronary vasospasm and ergonovine-induced spasmsurrogate
Intravenous prostacyclin is generally ineffective at preventing ischemic episodes due to coronary vasospasm in variant angina, despite its vasodilatory and antiplatelet effects.
Cite This Study
Chierchia et al. (1982) studied this question.